Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...
The company plans to submit a biologics licence application to the US Food and Drug Administration later this year.
SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial for ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
SAN DIEGO - Avidity Biosciences, Inc. (NASDAQ:RNA), a biotechnology company with a market capitalization of $3.74 billion, has announced positive topline data from its Phase 1/2 EXPLORE44 trial ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping demonstrating consistent ...
The company reported top-line data from its phase I/II Explore44 study, showing statistically significant increases in dystrophin reduction, as well as marked reductions in creatine kinase, a ...
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback